Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14) +

Sae Matsuoka, Naoki Osada, Hirokazu Kubota, Ko Kikuzato, Hiroo Koyama, Takeshi Sonoda, Akiko Idei, Minoru Yoshida, Masaki Kikuchi, Takashi Umehara, Chiduru Watanabe, Teruki Honma, Hiroshi Yasui, Sho Ikeda, Naoto Takahashi, Hideki Nakasone, Jiro Kikuchi, Yusuke Furukawa

Blood Neoplasia (2025) 2 (2): 100091.

https://doi.org/10.1016/j.bneo.2025.100091

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma

Blood Neoplasia (2025) 2 (2): 100072.

https://doi.org/10.1016/j.bneo.2025.100072

Published: 2025

Includes: Supplemental data

Journal Articles

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma

Blood Neoplasia (2025) 2 (1): 100051.

https://doi.org/10.1016/j.bneo.2024.100051

Published: 2025

Includes: Supplemental data

Journal Articles

Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma

Bei Wang, Benjamin A. Derman, Madina Sukhanova, Daniel Appelbaum, John Cursio, Wei Zhang, Andrzej Jakubowiak, Brian C.-H. Chiu

Blood Neoplasia (2025) 2 (1): 100065.

https://doi.org/10.1016/j.bneo.2024.100065

Published: 2025

Journal Articles

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

Julia Erin Wiedmeier-Nutor, Michael A. Golafshar, Katie L. Kunze, Edward D. Esplin, Robert L. Nussbaum, Erik Jessen, Brandie Heald, A. Keith Stewart, N. Jewel Samadder, P. Leif Bergsagel, Rafael Fonseca

Blood Neoplasia (2024) 2 (1): 100045.

https://doi.org/10.1016/j.bneo.2024.100045

Published: 2024

Includes: Supplemental data

Journal Articles

Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma

Blood Neoplasia (2024) 1 (4): 100049.

https://doi.org/10.1016/j.bneo.2024.100049

Published: 2024

Includes: Supplemental data

Journal Articles

Deciphering MARCH5’s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling

Hamed Bashiri, Ahad Khalilnezhad, Haruhito Totani, Joe Yeong, Tae-Hoon Chung, Felicia Wee, Yuezhen Xue, Zhen Wei Neo, Li Yen Chong, Wee Joo Chng, Atsushi Watanabe, Siok-Bian Ng, The Phyu, Toshio Suda

Blood Neoplasia (2024) 1 (4): 100046.

https://doi.org/10.1016/j.bneo.2024.100046

Published: 2024

Includes: Supplemental data

Journal Articles

Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma

Eunice Lai, Yu Yang Soon, Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Cinnie Yentia Soekojo, Melissa Ooi, Wee Joo Chng, Sanjay de Mel

Blood Neoplasia (2024) 1 (4): 100042.

https://doi.org/10.1016/j.bneo.2024.100042

Published: 2024

Includes: Supplemental data

Journal Articles

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies

Ella Troy, Joseph Caporale, Yasemin Sezgin, Marcelo S. F. Pereira, Gregory Behbehani, Justin Lyberger, Dean A. Lee, Meisam Naeimi Kararoudi

Blood Neoplasia (2024) 1 (4): 100032.

https://doi.org/10.1016/j.bneo.2024.100032

Published: 2024

Includes: Supplemental data

Journal Articles

Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

Blood Neoplasia (2024) 1 (3): 100025.

https://doi.org/10.1016/j.bneo.2024.100025

Published: 2024

Includes: Supplemental data

Journal Articles

Multiple myeloma–associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis

Hiroto Ohguchi, Yasuyo Ohguchi, Sho Kubota, Kan Etoh, Ai Hamashima, Shingo Usuki, Takako Yokomizo-Nakano, Jie Bai, Takeshi Masuda, Yawara Kawano, Takeshi Harada, Mitsuyoshi Nakao, Takashi Minami, Teru Hideshima, Kimi Araki, Goro Sashida

Blood Neoplasia (2024) 1 (1): 100005.

https://doi.org/10.1016/j.bneo.2024.100005

Published: 2024

Includes: Supplemental data

Journal Articles

Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data

Benjamin A. Derman, Jacob Ambrose, Laura L. Fernandes, Christina M. Zettler, Eric Hansen, Andrew J. Belli, Ching-Kun Wang

Blood Neoplasia (2024) 1 (1): 100003.

https://doi.org/10.1016/j.bneo.2024.100003

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14) +

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma

Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma

Deciphering MARCH5’s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling

Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies

Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

Multiple myeloma–associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis

Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only